Literature DB >> 1654368

The herpes simplex virus ribonucleotide reductase is required for ocular virulence.

C R Brandt1, R L Kintner, A M Pumfery, R J Visalli, D R Grau.   

Abstract

We used a herpes simplex virus (HSV) type 1 ribonucleotide reductase (RR) null mutant (ICP6 delta) to study the role of HSV-1 RR in ocular HSV infections. We found that ICP6 delta was unable to induce vascularization of the cornea or stromal keratitis following inoculation into the cornea of BALB/c mice, but was able to induce a transient mild blepharitis. The parental strain (HSV-1 KOS) and a revertant of ICP6 delta, ICP6 delta+3.1, both caused severe ocular disease, indicating that HSV-1 RR is required for ocular virulence in mice. ICP6 delta grew poorly in vitro (Vero and BALB/c 3T3 fibroblasts) and in vivo (eye, trigeminal ganglia and brain) compared to ICP6 delta+3.1 and HSV-1 KOS, suggesting that the avirulence of ICP6 delta is due to poor growth in the host. ICP6 delta also grew less well in primary human corneal fibroblasts, suggesting that RR may be required for virulence in humans. These results indicate that drugs inhibiting the function of RR might be effective in treating ocular HSV infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654368     DOI: 10.1099/0022-1317-72-9-2043

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.

Authors:  David J Davido; Eleain M Tu; Hong Wang; Maria Korom; Andreu Gazquez Casals; P Jahnu Reddy; Heba H Mostafa; Benjamin Combs; Steve D Haenchen; Lynda A Morrison
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

2.  Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors:  C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Phosphorylation of a herpes simplex virus 1 dUTPase by a viral protein kinase, Us3, dictates viral pathogenicity in the central nervous system but not at the periphery.

Authors:  Akihisa Kato; Keiko Shindo; Yuhei Maruzuru; Yasushi Kawaguchi
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

4.  Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates.

Authors:  A M Bonneau; P Kibler; P White; C Bousquet; N Dansereau; M G Cordingley
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Herpes simplex virus type 1 strain KOS-63 does not cause acute or recurrent ocular disease and does not reactivate ganglionic latency in vivo.

Authors:  W G Stroop; M C Banks
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

6.  Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins.

Authors:  Daniel J J Carr; Grzegorz B Gmyrek; Adrian Filiberti; Amanda N Berube; William P Browne; Brett M Gudgel; Virginie H Sjoelund
Journal:  Immunohorizons       Date:  2020-10-09

7.  Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation.

Authors:  Heba H Mostafa; Thornton W Thompson; Adam J Konen; Steve D Haenchen; Joshua G Hilliard; Stuart J Macdonald; Lynda A Morrison; David J Davido
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

8.  Induction of interleukin-6 in human retinal epithelial cells by an attenuated Herpes simplex virus vector requires viral replication and NFkappaB activation.

Authors:  Suping Cai; Curtis R Brandt
Journal:  Exp Eye Res       Date:  2007-12-03       Impact factor: 3.467

9.  Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.

Authors:  Jianmin Duan; Michel Liuzzi; William Paris; Francine Liard; Abigail Browne; Nathalie Dansereau; Bruno Simoneau; Anne-Marie Faucher; Michael G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Identification and characterization of pseudorabies virus dUTPase.

Authors:  A Jöns; T C Mettenleiter
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.